NCRC research project in Neuroblastoma has Scooped Award for Technology Innovation
Neuroblastoma is a type of aggressive cancer tumour that begins in nerve tissues of infants and very young children. On average, ten children every year in Ireland are diagnosed with Neuroblastoma. CMRF Crumlin proudly funds research into Neuroblastoma at the NCRC (National Children’s Research Centre).
Dr. Olga Piskareva has received an SFI TIDA (Science Foundation Ireland’s Technology Innovation Development) Award for her research work into neuroblastoma, funded by CMRF Crumlin. Her research is into the 3D cell culture model of neuroblastoma using collagen-based scaffolds for tumour-immune system interactions and therapeutics screening. CMRF Crumlin said that the award is testimony to the high standard of research excellence facilitated at the NCRC. This award of over €128,000 will allow Dr. Piskareva to extend her research into neuroblastoma.
“The development and approval of new oncology drugs are very slow processes.” Dr. Olga Piskareva said. “This is mainly due to the big differences in physiology of cancer cells grown on plastic and in native microenvironment. Tissue engineering of tumour systems has a great potential to bridge this gap. This proposal aims to develop a tissue engineered tumour model that can be used in testing new drugs and new combinations of existing drugs. This will reduce the attrition rate of the drug development process and lead to more effective and tailored therapies while lowering associated costs.”